SCHEMBL6035133

SCHEMBL6035133

N#Cc1cccc(CC(=O)O)c1OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 3/20 0.48
PTGER1 P34995 2/20 0.48
PTGER4 P35408 2/20 0.48
PTGER3 P43115 2/20 0.48
PTGER2 P43116 2/20 0.48
FABP4 P15090 1/20 0.48
FABP5 Q01469 1/20 0.48
MAOB P27338 3/20 0.44
AKR1B1 P15121 1/20 0.44
CFD P00746 2/20 0.44
PLG P00747 1/20 0.44
PLAU P00749 1/20 0.44
F11 P03951 1/20 0.44
KLKB1 P03952 1/20 0.44
F7 P08709 1/20 0.44
TPSB2 P20231 1/20 0.44
XDH P47989 1/20 0.42
NR4A2 P43354 1/20 0.41
THRA P10827 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23219226 0.85 NLRP3 (0.44) FFAR1PTGER1PTGER4PTGER3PTGER2
SCHEMBL29853048 0.85 NLRP3 (0.44) FFAR1PTGER1PTGER4PTGER3PTGER2
SCHEMBL8409148 0.81 HTR1A (0.53) FFAR1PTGER1PTGER4PTGER3PTGER2
SCHEMBL27484581 0.81 MAOB (0.48) FFAR1MAOBPLAU
Fluoride SCHEMBL28325117 0.80 MAOB (0.56) FFAR1MAOBAKR1B1XDH
SCHEMBL8408981 0.80 PTGER4 (0.53) FFAR1PTGER1PTGER4PTGER3PTGER2
SCHEMBL6036164 0.80 FABP4 (0.52) PTGER1PTGER4PTGER3PTGER2FABP4
SCHEMBL15610227 0.80 AKR1B1 (0.58) PTGER1PTGER4PTGER3PTGER2FABP4
SCHEMBL10591847 0.80 FABP4 (0.72) PTGER1PTGER4PTGER3PTGER2FABP4
SCHEMBL6036276 0.78 CXCL8 (0.51) PTGER1PTGER4PTGER3PTGER2FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 FFAR1 376/4885PTGER1 3821/4885PTGER4 2147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.